|
Neoplasms
|
0.500 |
Biomarker
|
group |
HPO |
|
|
|
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained <i>EF2K</i> gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer.
|
31432749 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
'BRCAness' is a term used to describe cancer cells that behave similarly to tumors with BRCA1 or BRCA2 mutations.
|
29620483 |
2018 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
(1998) Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.Mol.Cell, 2, 317-328].
|
25652403 |
2015 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
(99m)Tc-MIBI efflux rates were measured using a gamma camera in three Brca1 (-/-); p53 (-/-) mouse mammary tumors that have different Mdr1a/b expression levels.
|
19093112 |
2009 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
1.Identify the methylation status of BRCA1 in patients with epithelial ovarian cancer (EOC)and assess BRCA1 protein expression in tumor tissue.2.
|
25422243 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
5 of the 6 (83%) informative BRCA2 mutation tumours showed AI at the BRCA1 locus.
|
11710835 |
2001 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumor DNA was tested for the three common BRCA1/2 founder mutations present in Ashkenazi Jews, and p27(Kip1) expression was evaluated by immunohistochemistry.The median follow-up was 6.4 years.
|
11118465 |
2000 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumors in BRCA1 mutation carriers were more likely than tumors in age-matched controls to be invasive serous adenocarcinomas (odds ratio, 1.84; 95% confidence interval, 1.21-2.79) and unlikely to be borderline or mucinous tumors.
|
15073127 |
2004 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumors with BRCA1 promoter methylation are present in all expression clusters; however, a subgroup of ER-positive high-grade tumors has a significantly greater number of BRCA1 methylated tumors.
|
15868446 |
2005 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor DNA was obtained from BRCA1 (n = 14) and BRCA2 (n = 12) mutation carriers, as well as sporadic cases (n = 26).
|
16140926 |
2005 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumour size (hazard ratio (HR) 1.02 per mm increase, P = 0.016) and node status (HR 2.6 for three or more involved nodes versus node negative, P = 0.017) were independent predictors of overall survival in the familial non-BRCA1/2 group, and in the whole group, whereas contralateral breast cancer (HR 0.7, P = 0.503) and risk-reducing contralateral mastectomy (HR 0.4, P = 0.163) were not.
|
16758466 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumor DT was estimated for 43 women with a BRCA1 mutation, 16 women with a BRCA2 mutation, and 41 women at high risk without an identified mutation.
|
18094417 |
2007 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor suppressor BRCA1 and BRCA2 are frequently mutated in familial breast and ovarian cancer.
|
18720553 |
2008 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Tumor Nmut was associated with treatment response and with both PFS and OS in patients with high-grade serous ovarian cancer carrying BRCA1 or BRCA2 mutations.
|
24265793 |
2013 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Tumour expression level of BRCA1 was positively correlated with survival duration.
|
26740498 |
2016 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor and/or peripheral blood was tested for BRCA1 and BRCA2 truncating mutations.
|
26757435 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumors with BRCA1 or BRCA2 alterations were associated with a higher number of genomic aberrations (P < 0.001 and P < 0.001) and higher percentage of TP53 alterations (P < 0.001 and P < 0.001) than those without.
|
28124401 |
2017 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor suppressor BRCA1 has important roles in multiple pathways, including gene transcription, DNA damage repair, and control of apoptosis.
|
28706506 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumor suppressor genes BRCA1 and BRCA2 are the genes with most hereditary predisposition to breast and ovarian cancer.
|
28730229 |
2017 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor suppressor gene products including BRCA1 and BRCA2 (BRCA1&2) play an important role in telomere maintenance.
|
29423116 |
2018 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor xenograft models and breast cancer clinical data analyses further demonstrated an in vivo synthetic lethality interaction and clinical association between BET/TXNIP and BRCA1 deficiency in the survival of breast cancer patients.
|
30042414 |
2018 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor suppressor BRCA1 and cell cycle regulator CCND1 play a critical role in maintaining genome integrity and tumorigenesis, respectively.
|
31023256 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor BRCA1/2 testing was performed for 315 (77.6%) of the 406 eligible OC samples, of which 305 (96.8%) were successful.
|
31076742 |
2020 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumors from women with BRCA1 mutations were significantly less likely to be estrogen receptor positive (age-adjusted odds ratio [or]: 0.091; P < 0.001) and more likely to have a high nuclear grade (OR: 5.55; P 0.001) than tumors in which no mutation was identified.
|
9241077 |
1997 |